Catapult Awards – pushing forward treatments

Through our research programs, we are addressing the barriers that are preventing safer treatments from reaching children. Our research strategy encompasses programs and funding that deliver results to save children NOW.

The third and final phase of CureSearch’s research strategy is the Catapult Awards program. These critical awards propel high-potential research into clinical trials and ultimately approval.

Catapult Awards – Active Grants

Current and Future Awards

Catapult Awards will provide funding support up to $5 million for a two- to three-year award period for ‘clinic-ready’ projects.

2018/2019 APPLICATION CYCLE:
The 2018/2019 Catapult Award request for applications launched in October 2018 with a focus on Phase 1 or Phase 2 clinical trials that address areas of high unmet need in pediatric cancer research and treatment, including high-risk, relapsed, or metastatic disease, adolescent and young adult patient populations and/or the use of novel immunotherapy targets or modalities for pediatric cancer treatment. The application window is now closed and awards will be announced in May 2019.

FUTURE AWARDS:
CureSearch continues to invest in large-scale awards to ensure sustainable research moves forward at an accelerated pace. We are proud to invest in work that will move the needle and impact the future of children’s treatments.

Upcoming Catapult Award Opportunity:

Molecular Targets Catapult Award – Summer 2019

Request for Applications: General Information

Request for Applications: General Information

CureSearch Catapult Awards will provide support for projects that:

Will advance promising therapies for pediatric cancer into or further along in clinical development

Show a strong potential for future approval

Highest priority will be given to projects that address areas of high unmet need in pediatric cancer. Catapult Awards will provide funding support up to $5 million for a two- to three-year award period, for “clinic-ready” projects that fit the following parameters:

CureSearch won't stop until a greater quantity of effective and less-toxic children's cancer treatments have moved out of the lab and into the clinic, ensuring more children live long, healthy and productive lives.

Click here to be added to our mailing list to be the first to know about new RFAs.

For more information on Catapult Awards, developing resources or future RFAs, contact: